Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Connecticut › New Haven
Qorannoo klinikaalii Leukemia Myeloidii Hamaa New Haven, CT keessatti
Qorannoo 17 Leukemia Myeloidii Hamaa f New Haven fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · Miili 3 fagaatti
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1
- Yale University, New Haven
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Yale University, New Haven
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Yale University, New Haven
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · Miili 3 fagaatti
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Yale University, New Haven
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University, New Haven
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Yale University, New Haven
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Namoota walitti qabaa jiraSadarkaa 3
- Yale University School of Medicine, New Haven
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Smilow Cancer Hospital at Yale New Haven, New Haven
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Yale University, Yale Cancer Center, New Haven
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Yale New Haven Hospital, New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Yale New Haven Hospital, New Haven
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Yale University, New Haven
Revumenib in Combination With 7+3 + Midostaurin in AML
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center, New Haven
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
- Yale University, New Haven
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Seattle, WAQorannoo 41
- Baldwin Park, CAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 31
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
Qorannoo biroo New Haven keessatti
- Kansara Qara'a Non-Small CellQorannoo 41
- Saree OljooQorannoo 38
- Saree (Gosoota Hunda)Qorannoo 33
- Kansara MetastatikiiQorannoo 23
- Dhibee QaraQorannoo 22
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 22
- Kansarii OvariiQorannoo 21
- Kansarii ColorectalQorannoo 20
- Kansarii ProstateQorannoo 20
- Alcohol Use Disorder (AUD)Qorannoo 17
- Overdose OpioidQorannoo 17
- Kansarii PancreasQorannoo 16
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.